[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645111":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":30,"studyPopulation":22,"armGroups":31,"interventions":44,"overallOfficials":53,"centralContacts":57,"locations":22,"responsibleParty":67,"collaborators":22,"id":69,"slug":22,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":22,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":22,"enrollmentInfo":76,"targetDuration":22,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":89,"whyStopped":22,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":22},{"fullName":5,"class":6},"National Cheng-Kung University Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Rebleeding within 28 days","The primary outcome was rebleeding within 28 days, defined as recurrence of bleeding from the index lesion. Clinical indicators included persistent melena, hematochezia, hemodynamic instability (systolic blood pressure \\\u003C 90 mm Hg or heart rate \\> 120 bpm), and a drop in serum hemoglobin greater than 2 g\u002FdL. Subsequent colonoscopy should be performed for confirmation and hemostasis intervention.","28 days",[14,16,18,20],{"measure":15,"description":15,"timeFrame":12},"index lesion rebleeding requiring transarterial embolization or emergent surgery",{"measure":17,"description":17,"timeFrame":12},"the duration of hospitalization",{"measure":19,"description":19,"timeFrame":12},"transfusion units of packed red blood cells",{"measure":21,"description":21,"timeFrame":12},"bleeding related mortality",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":26,"primaryPurpose":27,"observationalModel":22,"timePerspective":22,"maskingInfo":28},"RANDOMIZED","PARALLEL","Both groups will receive standard endoscopic hemostasis, including local injection of diluted epinephrine combined with heater probe coagulation, hemoclipping, and\u002For band ligation. Afterward, patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate. Following the endoscopic procedure, patients will be directly observed for 5 minutes to confirm successful hemostasis. All patients will be followed for 28 days to assess the occurrence of post-procedural rebleeding.","PREVENTION",{"masking":29,"maskingDescription":22,"whoMasked":22},"NONE","This single-center randomized controlled study was conducted at our hospital and was approved by the hospital's Institutional Review Board (A-BR-115-031). Patients with confirmed LGIB were recruited.\n\nThis clinical trial will enroll patients at National Cheng Kung University Hospital. All patients who are hospitalized for lower gastrointestinal bleeding and undergo colonoscopy will be invited to participate. This study uses random allocation, with one Intervention group and one Standard group. Both groups will receive standard endoscopic hemostasis. All the enrolled patients underwent standard endoscopic hemostasis by local injection of diluted epinephrine combined with heater probe coagulation, hemoclipping, and\u002For band ligation. Afterward, patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate. Following the endoscopic procedure, patients will be directly observed for 5 minutes to confirm successful hemostasis. All patients will be followed for 28 days to assess the occurrence of post-procedural rebleeding.",[32,38],{"label":33,"type":34,"description":35,"interventionNames":36},"Intervention Group","EXPERIMENTAL","All the enrolled patients underwent standard endoscopic hemostasis by local injection of diluted epinephrine combined with heater probe coagulation, hemoclipping, and\u002For band ligation. Patients in the intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate.",[37],"Drug: Tranexamic acid and sucralfate powder spray",{"label":39,"type":40,"description":41,"interventionNames":42},"Standard group","ACTIVE_COMPARATOR","All the enrolled patients underwent standard endoscopic hemostasis by local injection of diluted epinephrine combined with heater probe coagulation, hemoclipping, and\u002For band ligation.",[43],"Other: Standard endsocopic hemostasis",[45,50],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":22},"DRUG","Tranexamic acid and sucralfate powder spray","All the enrolled patients underwent standard endoscopic hemostasis by local injection of diluted epinephrine combined with heater probe coagulation, hemoclipping, and\u002For band ligation. Patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate.",[33],{"type":6,"name":51,"description":41,"armGroupLabels":52,"otherNames":22},"Standard endsocopic hemostasis",[39],[54],{"name":55,"affiliation":5,"role":56},"Hsueh-Chien Chiang","PRINCIPAL_INVESTIGATOR",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":22,"email":62},"Hsueh-Chien Chiang, MD","CONTACT","+886910890307","scion456scion@gmail.com",{"name":64,"role":60,"phone":65,"phoneExt":22,"email":66},"Xi-Zhang Lin","8862353535","linxz@mail.ncku.edu.tw",{"type":56,"investigatorFullName":55,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Attending Physician","100645111",false,"NCT07679139","Endoscopic Application of Hemostatic Drug Powder in Lower Gastrointestinal Bleeding: A Pilot Study","Inclusion Criteria:\n\n* patients suspect lower gastrointestinal bleeding\n\nExclusion Criteria:\n\n* absence of indication for endoscopic hemostasis\n* known allergy to sucralfate, TXA\n* presence of a hollow organ perforation","ALL","18 Years",{"count":77,"type":78},60,"ESTIMATED","INTERVENTIONAL",[81],"NA","This clinical trial will enroll patients at National Cheng Kung University Hospital. All patients who are hospitalized for lower gastrointestinal bleeding and undergo colonoscopy will be invited to participate. This study uses random allocation, with one Intervention group and one Standard group. Both groups will receive standard endoscopic hemostasis. Afterward, patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate. Following the endoscopic procedure, patients will be directly observed for 5 minutes to confirm successful hemostasis. All patients will be followed for 28 days to assess the occurrence of post-procedural rebleeding.",[84],"Bleeding After GI Endoscopy",[86,87,88],"lower gastrointestinal bleeding","tranexamic acid","sucralfate","NOT_YET_RECRUITING","2026-06-25",{"date":92,"type":93},"2026-07-01","ACTUAL",{"date":92,"type":78},{"date":96,"type":78},"2027-12-31",{"name":5,"class":6}]